Want to see SE:PAX full AI Analyst Report?
Top Page
Paxman AB
(PAX)
Select Model
Select Model
Rating:59Neutral
Price Target:
kr48.00
▲(2.67% Upside)
Action:Reiterated
Date:05/25/26
The overall score of 58.8 reflects a mixed outlook. The company's strong balance sheet (debt-to-equity 0.01) provides stability, but recent profitability and cash flow declines weigh on financial performance. Technical indicators show short-term bullish momentum, though the stock remains below its 200-day moving average. Valuation is weak due to negative earnings and no dividend. The balance sheet strength and positive technicals partially offset valuation concerns, resulting in a moderate score.
Positive Factors
Solid revenue growth
Consistent, high single- to double-digit revenue growth (Fundamentals.RevenueGrowth ~28%) supports a growing installed base and rising consumable and service usage per site. Durable top-line expansion strengthens recurring revenues, yields scale economics and funds continued clinical adoption over multiple quarters.
Negative Factors
Deteriorating profitability
The transition to net losses in 2025 and TTM demonstrates margin deterioration and weak profitability conversion. Prolonged unprofitability erodes retained earnings, constrains reinvestment capacity and forces management to restore utilization, pricing or cost controls to sustainably return to profitable operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid revenue growth
Consistent, high single- to double-digit revenue growth (Fundamentals.RevenueGrowth ~28%) supports a growing installed base and rising consumable and service usage per site. Durable top-line expansion strengthens recurring revenues, yields scale economics and funds continued clinical adoption over multiple quarters.
Read all positive factors
Paxman AB (PAX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.02B
Dividend YieldN/A
Average Volume (3M)100.37K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue Growth28.39%
EPS Growth-141.02%
CountrySE
Employees143
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.47
Shares Outstanding23,273,417
10 Day Avg. Volume41,338
30 Day Avg. Volume100,373
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)3.05
Price to Sales (P/S)3.95
P/FCF Ratio-76.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.86
Revenue Forecast (FY)kr412.65M
Paxman AB Business Overview & Revenue Model
Company Description
Paxman AB (publ), along with its subsidiaries, specializes in the creation and worldwide sale of the Paxman scalp cooling system, an innovative solution designed to minimize hair loss in patients undergoing chemotherapy. This system is distributed...
How the Company Makes Money
Paxman primarily makes money by commercializing its scalp cooling therapy platform to oncology infusion centers and hospitals. Its revenue model typically combines (1) sales or placement of scalp cooling systems (capital equipment) to healthcare p...
Paxman AB Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
85
Very Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 335.77M | 313.35M | 253.01M | 210.12M | 156.75M | 96.20M |
| Gross Profit | 164.59M | 208.81M | 175.42M | 146.42M | 101.44M | 64.52M |
| EBITDA | 29.06M | 28.46M | 49.73M | 31.23M | 16.18M | 1.25M |
| Net Income | -10.73M | -16.71M | 40.20M | 8.33M | -10.32M | -12.78M |
Balance Sheet | ||||||
| Total Assets | 475.17M | 479.11M | 227.23M | 167.12M | 173.96M | 166.34M |
| Cash, Cash Equivalents and Short-Term Investments | 106.09M | 120.83M | 40.31M | 24.98M | 38.09M | 72.27M |
| Total Debt | 4.58M | 13.01M | 14.29M | 13.57M | 16.98M | 17.15M |
| Total Liabilities | 66.57M | 73.95M | 63.24M | 44.51M | 59.76M | 40.59M |
| Stockholders Equity | 408.60M | 405.16M | 163.99M | 122.62M | 114.20M | 125.75M |
Cash Flow | ||||||
| Free Cash Flow | -20.43M | -16.09M | 15.99M | -9.70M | -33.01M | -27.94M |
| Operating Cash Flow | -2.23M | 7.39M | 39.10M | 15.63M | 2.69M | -4.14M |
| Investing Cash Flow | -32.47M | -33.51M | -24.50M | -25.33M | -36.69M | -24.45M |
| Financing Cash Flow | -12.12M | 108.83M | 721.00K | -3.41M | -169.00K | 97.28M |
Paxman AB Technical Analysis
Negative
46.75
Price Trends
48.62
Negative
49.04
Negative
51.51
Negative
Market Momentum
-0.83
Positive
32.19
Neutral
19.94
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PAX, the sentiment is Negative. The current price of 46.75 is below the 20-day moving average (MA) of 46.90, below the 50-day MA of 48.62, and below the 200-day MA of 51.51, indicating a bearish trend. The MACD of -0.83 indicates Positive momentum. The RSI at 32.19 is Neutral, neither overbought nor oversold. The STOCH value of 19.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PAX.
Paxman AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | kr9.30B | 105.05 | 4.13% | ― | 8.79% | -20.48% | |
59 Neutral | kr1.02B | -93.34 | -2.58% | ― | 28.39% | -141.02% | |
53 Neutral | kr1.15B | -32.34 | -3.99% | ― | -0.34% | 29.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr624.93M | -5.60 | -37.43% | ― | 27.40% | 26.07% | |
47 Neutral | kr544.93M | -64.79 | -2.84% | ― | -13.72% | 52.47% | |
47 Neutral | kr276.41M | -6.02 | -25.09% | ― | 6.49% | 25.03% |
* Healthcare Sector Average
SE:PAX
Paxman AB
43.70
-30.10
-40.79%
SE:SEZI
Senzime AB
3.98
-2.57
-39.31%
SE:XVIVO
Xvivo Perfusion AB
295.20
113.40
62.38%
SE:BACTI.B
Bactiguard Holding AB
15.55
-11.95
-43.45%
SE:BRAIN
BrainCool AB
0.70
-0.28
-28.35%
SE:SEDANA
Sedana Medical AB
11.56
-4.34
-27.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.